Timber pharmaceuticals announces positive end-of-phase 2 meeting with fda for tmb-001 in moderate to severe congenital ichthyosis

- full data from phase 2b control study presented at 2022 winter clinical dermatology conference -

TMBR Ratings Summary

TMBR Quant Ranking